… Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi